article thumbnail

Q&A: Why drafting new rules on ultra-processed foods is so hard

STAT

Whole grain cereal and breads also qualify for the label, as do yogurts and some other dairy desserts. Processed meats, as their name would suggest, also belong in this category. But ultra-processed foods are not all the same.

article thumbnail

FDA AdCom votes in favour of Lundbeck’s/Otsuka’s Rexulti in AAD

Pharmaceutical Technology

The current unmet need, the benefit of treatment with Rexulti, and a reasonable safety profile persuaded Dr. Merit Cudkowicz, Julieanne Dorn professor of neurology at Harvard University’s Medical School, to give a positive vote. Rexulti is an atypical antipsychotic.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Over-the-Counter Choices Pharmacist Role and Resources

FADIC

OTC drugs come in various forms, including tablets, capsules, creams, and liquids, and are generally labeled with clear instructions on proper usage and dosage. The FDA’s website provides a wealth of information on OTC drugs, including product labels, warnings, and recalls.

article thumbnail

Almirall/Lilly lebrikizumab offers potential long-term management of atopic dermatitis

pharmaphorum

He has been a research fellow at Harvard Medical School, Boston, the University of California, San Francisco, and University Spital Zürich, Switzerland, where his research focused on atopic dermatitis and the complexity of the skin barrier.

article thumbnail

Biogen and Eisai’s Alzheimer’s drug secures support in closely watched AdCom

Pharmaceutical Technology

The evidence for clinical benefit was “very clear”, said Dr. Merit Cudkowicz, Julieanne Dorn professor of neurology at Harvard University’s Medical School. Robert Alexander, research professor at the University of Arizona’s College of Medicine, who voted in favour of Leqembi at the 9 June meeting.

article thumbnail

Pharmacovigilance deep dive: risk minimisation measures

European Pharmaceutical Review

She also has been conducting fundamental research as an academic in several universities, with her last academic position held at Harvard Medical School. She holds a MSc in Public Health and a PhD in Biophysics and Molecular Biology. About the author. Hannah Balfour is the Science Writer for European Pharmaceutical Review. References.

article thumbnail

Resourceful or risky? The UK’s controversial COVID-19 vaccine strategy

pharmaphorum

I DID NOT consent to receive an off-label drug with NO evidence of benefit with a single dose. The British Medical Association (BMA) also blasted the decision as “unreasonable and totally unfair”. Just received this email cancelling my 2nd dose of the Pfizer vaccine. On the basis of UK government guidance yesterday.